Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Verizon Communications Inc (VZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Verizon Communications Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $296.08 (market cap $8.04B), while Verizon Communications Inc trades at $42.81 (market cap $177.34B). The key difference: Verizon Communications Inc is far larger — about 22.1× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Verizon Communications Inc pays a 6.66% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | VZ | |
|---|---|---|
Market Cap | $8.04B | $177.34B |
Sector | Health | Media |
52-Week High | $339.75 | $51.38 |
52-Week Low | $241.71 | $38.40 |
Enterprise Value | $7.85B | $364.84B |
Volume | — | 22,584,735 |
Dividend Yield | — | 6.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
Verizon (VZ) trades at $42.68, up 1.33% today, with a bearish technical signal from moving averages but recent earnings beats. The stock offers a 6.7% dividend yield with a consensus price target of $47.57, indicating 11.5% upside. Revenue grew to $138.19B in 2025, with a net income margin of 12.46%, while debt levels remain elevated at $144B total debt. Recent news highlights competitive threats from SpaceX's Starlink but also new partnerships like the 5G deal with BMW.
Outlook: VZ presents a value opportunity with a low P/E of 10.4 and strong cash flow, but faces significant competitive and debt-related risks. The stock is suitable for income-focused investors seeking defensive yield, though growth is constrained by industry saturation and rising capital expenditures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Verizon Communications Inc
Verizon Communications Inc. is an integrated telecommunications company that provides wire line voice and data services, wireless services, Internet services, and published directory information. The Company also provides network services for the federal government including business phone lines, data services, telecommunications equipment, and payphones.
Read more on VZ →
